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Natural killer (NK) cells are a type of innate lymphoid cells (ILCs) that play a pivotal role fighting against 
cancer and viral infections. NK cells derive from the CD34+ hematopoietic progenitor cells (HPCs) and since 
they have cytotoxic activity, it is suggested that NK and cytotoxic T cells might have evolved from a 
common ancestral cytolytic effector cell (Freud & Caligiuri, 2006; Caligiuri, 2008). Phenotypically, human 
NK cells are commonly defined by the absence of T cell receptor/CD3 complex or TCR/CD3 (difference 
from T cells) and the expression of CD56, an isoform of the neural cell adhesion molecule (NCAM). The 
expression density of the latter marker defines two functionally different NK cell subsets: CD56bright and 
CD56dim. It has been shown that NK cells follow 6 different stages of maturation. CD56dimCD16+CD57+ NK 
cells represent the final stage of that maturation, while CD56brightCD16-CD57- cells represent the 4th stage of 
maturation; therefore, CD56dim NK cells are more differentiated (Freud & Caligiuri, 2006; Freud et al., 
2017). CD56bright NK cells are abundant in lymph nodes and tonsils, that is, in secondary lymphoid tissues 
(SLT), and other tissues such as the gravid uterus; but they can also be found in peripheral blood in a very 
low percentage (Freud et al., 2017). CD56bright NK cells are able to produce abundant amounts of cytokines 
and chemokines, and they have little capacity to spontaneously kill tumor cell targets (Caligiuri, 2008). 
CD56dim NK cells, however, are abundant in bone marrow, peripheral blood and spleen, and are able to 
greatly kill tumor cells, although they have lower ability to produce cytokines and chemokines (Freud et al., 
2017; Wagner et al., 2017). Moreover, NK cell subsets are also characterized by their expression of FcγRIII, 
also known as CD16 (CD56brightCD16dim/- and CD56dimCD16bright respectively), which gets bound to the Fc 
region of IgG antibodies and induces antibody-dependent cellular cytotoxicity (ADCC) (Caligiuri, 2008; 
Freud et al., 2017). Summarizing, we can define NK cell subsets as CD56dim NK cells to be more cytotoxic 
and the CD56bright to be potent interferon (IFN)-γ producers. However, the total population of NK cells still 
remains phenotypically heterogeneous (Caligiuri, 2008; Freud & Caligiuri, 2006; Freud et al., 2017; Keating 
et al., 2016). Indeed, it has been calculated that there could be over 6,000-30,000 NK cell subpopulations in 
every individual (Horowitz et al., 2013). 
NK cells are able to recognize and bind to polymorphic determinants of major histocompatibility complex 
(MHC) class I molecules (HLA class I molecules in humans), and depending on whether the recognition and 
binding is carried out by activating (i.e. KIR2DS, CD94/NKG2C) or inhibitory (i.e. KIR2DL, KIR3DL, 
CD94/NKG2A, ILT2) receptors, NK cells will (or not) secrete cytokine and release cytolytic granules 
(Borrego et al., 2002). HLA class I molecules are expressed in all healthy nucleated cells, and the inhibitory 
signals are predominant over the activating signals. Therefore, the consequence is that NK cells do not kill 
healthy cells (Borrego et al., 2002; Caligiuri, 2008; Freud et al., 2017; Valiante et al., 1997). However, when 
cells are infected or transformed, the levels of HLA class I molecules decrease and stress induced ligands for 
NK cell activating receptors are expressed. In this situation, NK cells get activated and become able to 
recognize and kill those infected and malignant cells (Cerwenka et al., 2016). In addition to the above 
mentioned KIR2DS and CD94/NKG2C, some very relevant activating cell surface receptors are the natural 




DNAM-1 and CD16 (Caligiuri, 2008; Freud et al., 2017; Terrén et al., 2020). NK cells can also get activated 
by cytokines, as they express receptors for several activating cytokines such as type I interferon (IFN), 
interleukin (IL)-2, IL-7, IL-12, IL-15, IL-18 and IL-21 (Vivier et al., 2011). At the end, NK cell activation is 
the result of the balance between inhibitory and activating signals, working along a dynamic equilibrium 
(Long et al.,2013). 
Once activated, NK cells can mediate their functions by three different ways: 1) Via activating receptors that 
lead to perforin/granzyme B secretion (degranulation) and production of cytokines and chemokines, such as 
IFNγ, tumor necrosis factor (TNF), macrophage inflammatory protein (MIP)-1β, etc. 2) Via CD16 which 
recognizes the Fc fragment of antibodies and leads to antibody-dependent cell-mediated cytotoxicity or 
ADCC, which also induces perforin/granzyme and cytokine secretion (Caligiuri, 2008; Freud et al., 2017; 
Yawata et al., 2006). Perforin and granzyme are molecules present in cytolytic granules in the cytoplasm of 
NK cells and induce apoptosis of target cells after their release. CD107a has been described as a marker of 
NK cell degranulation (Aktas et al., 2009; Alter et al., 2004; Cohnen et al., 2013). Following with NK cell 
produced cytokines, IFNγ is considered the model NK cell cytokine. CD56bright NK cells produce this 
cytokine when stimulated through CD16 or in response to different interleukins released by antigen 
presenting cells (APCs). 3) Last, NK cells also express death receptor ligands such as the first apoptosis 
signal (FAS)-ligand (FasL) and the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). 
Both receptors induce the process of apoptosis by activation of caspases leading to cell death (Finnberg et 
al., 2008; Screpanti et al., 2005).  
Traditionally, NK cells have been classified as cells of the innate arm of the immune response. However, it 
has been demonstrated that NK cells can develop immunological memory to some haptens and virus, and 
perform antigen-specific memory responses (Berrien-Elliott et al., 2015; Cerwenka & Lanier, 2016; Nikzad 
et al., 2019; Romee et al., 2016). Moreover, it has been demonstrated that a brief exposure (16-18 hours) of 
NK cells to a mixture of IL-12, IL-15 and IL-18 results in the development of memory-like properties 
(Cooper et al., 2009). This memory-like behavior could be considered as a pre-activation state, and those 
pre-activated cells are named cytokine-induced memory-like (CIML) NK cells (Cerwenka & Lanier, 2016; 
Cooper et al., 2009). CIML NK cells show a major capacity to respond following reactivation with cytokines 
or via engagement of activating receptors after a resting period (Cooper et al., 2009). Also, these CIML NK 
cells show an enhanced functionality, exhibiting a significantly increased IFNγ and TNF production, and an 
increased expression of granzyme B and perforin (Romee et al., 2016). However, this increase in IFNγ is not 
homogeneous in both NK cell subsets, being more enhanced in CD56bright NK cells. Although both subsets 
showed similar IFNγ production when restimulated with a mixture of IL-12 and IL-15 (Romee et al., 2012). 
Moreover, compared to control non-preactivated NK cells, CIML NK cells have shown a higher cytotoxicity 
after restimulation with targets cells like K562 leukemia cells and primary acute myeloid leukemia (AML) 
blasts (Romee et al., 2016). All these enhanced functions are correlated with lower expression of inhibitory 
KIR receptors (Berrien-Elliott et al., 2015; Ewen, Pahl, Miller, Watzl, & Cerwenka, 2018). CIML NK cells 




reduced risk of developing graft-versus-host disease (Wagner et al., 2017). Furthermore, in studies of 
adoptive cell therapies with CIML NK cells, complete remissions have been observed in patients with 
refractory AML (Romee et al., 2016). Currently, there are six ongoing clinical trials (NCT04024761, 
NCT04290546, NCT03068819, NCT04354025, NCT01898793 and NCT02782546, from 
https://clinicaltrials.gov/ct2/results?cond=&term=CIML&cntry=&state=&city=&dist=) in which 
CIML NK cells are being used to treat different malignancies.  
Until now, CIML NK cells infusion has found to be safe, but moderate efficacy has been achieved (Romee et 
al., 2016). Therefore, it is necessary to find new ways to improve treatment outcomes. In the last years, 
immunometabolism has emerged as an interesting target. Metabolism is a key feature for the homeostasis of 
an organism, and the effector functions of immune cells are highly linked to their metabolism (Gardiner, 
2019; O’Brien & Finlay, 2019). However, our understanding of NK cell metabolism is still very limited. NK 
cells use both oxidative phosphorylation (OXPHOS) and glycolysis to fuel their proliferation processes 
(O’Brien & Finlay, 2019; O’Neill, Kishton, & Rathmell, 2016). The latter is key for numerous immune 
responses, thus an enhanced glycolysis enables the immune cells to produce enough ATP and other 
biosynthetic intermediates in order to carrying out their effector functions (Gardiner, 2019; O’Brien & 
Finlay, 2019). Hence, an increased glycolysis might be the key for the enhanced effector functions of CIML 
NK cells. Glycolysis supports cytokine production, cytotoxicity and proliferative capacity (Keppel et al., 
2015). On the other hand, inhibition of OXPHOS with oligomycin induces an inhibition of both cytotoxicity 
and IFNγ production (Chang et al., 2013; Gardiner, 2019; Mah & Cooper, 2016; O’Brien & Finlay, 2019). 
The effects of the inhibition of glycolysis with 2-deoxy-D-glucose (2-DG) on NK cells are not well known, 
although it is accepted that a dysfunctional metabolism leads to an inhibition of NK cells effector functions 
(Gardiner, 2019; Keppel et al., 2015; O’Neill et al., 2016; Terrén et al., 2019). Last, these processes become 
upregulated when NK cells are activated with IL-2, IL-12, IL-15 and IL-18 (Gardiner, 2019; Pahl et al., 
2018), although the metabolic changes induced by cytokine stimulation have been found to be different 
among distinct NK cell subsets. For example, it has been shown that CD56bright NK cells are more responsive 
to metabolic changes and they do upregulate several metabolic markers in response to cytokines, while 
CD56dim NK cells have a low responsiveness (Keating et al., 2016). 
Hence, the objective of this work is first to determine the glycolytic requirements of CIML NK cells by 
studying their glucose uptake rate. Moreover, it will be studied how the inhibition of the glycolytic pathway 
with 2-DG affects the effector functions of CIML NK cells. Therefore, this work will help to understand the 
metabolic changes that happen in CIML NK cells and their relationship with effector functions. 
MATERIALS AND METHODS 
Samples and cell culture 
Buffy coats from healthy adult donors were collected through the Basque Biobank for Research. Peripheral 




purified from PBMCs using the Human NK Cell Isolation Kit (Miltenyi Biotec). Purified NK cells were 
cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with GlutaMAX 
(ThermoFisher Scientific), 10% fetal bovine serum (FBS) (GE Healthcare Life Sciences), 1% non-essential 
amino acids (ThermoFisher Scientific), 1% sodium pyruvate (ThermoFisher Scientific) and 1% 
penicillin/streptomycin (ThermoFisher Scientific), from now on, NK medium. Cells were cultured for 16-18 
hours, in the presence and absence of recombinant human IL-12 (Milteny Biotec), IL-15 (Miltenyi Biotec) 
and IL-18 (MBL International) (10, 100 and 50 ng/ml, respectively). Next, cells were washed 3 times with 
phosphate buffered saline (PBS) (Lonza), resuspended in NK medium and cultured for 7 days at 2 x 106 
cells/ml in the presence of IL-15 (1 ng/ml) or IL-2 (20 IU/ml) (Figure 1). 
Figure 1. Diagram showing experimental design of NK and CIML NK cells (made with BioRender). NK cells were 
first cultured in the presence (CIML NK cells) or absence (NK cells) of recombinant IL-12, IL-15 and IL-18 (10, 100 
and 50 ng/ml, respectively) for 16-18h. Next, cells were washed with PBS, resuspended in NK medium and cultured in 
presence of IL-15 (CIML15 NK and NK15 cells) or IL-2 (CIML2 NK cells) for 7 days. 
Glucose uptake assay 
For glucose uptake assay, cells were plated at 1 x 106 cells/ml and incubated for 90 minutes with 50 µM of 
2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxy-D-glucose (2-NBDG) (Invitrogen), which is a 
fluorescent glucose analog. After incubation time, cells were washed and stained with LIVE/DEAD fixable 
Near-IR cell stain (ThermoFisher Scientific) for 30 minutes on ice. Cells were then washed with PBS+BSA 
(2.5%) and stained with the following fluorochrome-conjugated mouse anti-human monoclonal antibodies: 
PE-Vio770 anti-CD56 (REA196, Miltenyi Biotec), BV510 anti-CD14 (MΦP9, BD biosciences) and BV510 
anti-CD3 (UCHT1, BD biosciences). Cells were then washed with PBS and acquired in a MACSQuant® 





For functional assay, NK cells were plated at 2 x 105 cells/well in a U-bottom 96-well plate. Cells were then 
stimulated for 7 hours at 37ºC either with K562 target cells (1:1 effector:target ratio) or with IL-12, IL-15 
and IL-18 (10, 100 and 50 ng/ml, respectively). NK cells were stimulated in the presence and absence of 50 
mM 2-deoxy-D-glucose (2-DG) (Sigma-Aldrich), a glycolytic inhibitor. PE anti-CD107a (REA792, Miltenyi 
Biotec) was added to the wells at the beginning of the stimulation period, and after 1 hour two protein 
transport inhibitors were also added, one containing Monensin (Golgi Stop, BD biosciences) and the other 
containing Brefeldin A (Golgi Plug, BD biosciences). After 7 hours of stimulation cells were collected and 
stained with LIVE/DEAD fixable Near-IR cell stain and with the previously mentioned mAbs. Then, cells 
were fixed and permeabilized, and stained with the following mouse anti-human monoclonal antibodies: 
FITC anti-MIP-1β (D21-1351, BD biosciences), BV421 anti-IFNγ (B27, BD biosciences) and APC anti-
TNF (Mab11, Biolegend). Finally, cells were washed with PBS and acquired in a MACSQuant ® flow 
cytometer. Data analysis was performed with FlowLogic software. 
 
Statistical analysis 
Statistical analysis and figure representation were made with GraphPad Prism (v8.1) and Funky Cells 
(v0.1.2). Non-parametric Wilcoxon matched-pairs signed rank tests were performed to check for significant 
differences between different conditions. Data was represented displaying means ± standard error of the 
mean (SEM). *p < 0.05 and **p < 0.01.  
 
RESULTS 
CIML NK cells exhibit increased glycolytic activity 
Glycolytic pathway in NK cells is fundamental, since it has been reported that glycolytic activity is increased 
when cells are stimulated (Gardiner, 2019; Keppel et al., 2015; O’Neill et al., 2016; Terrén et al., 2019). 
Therefore, the first goal was to evaluate the metabolic activity of NK cells after stimulation with IL-12, IL-
15 and IL-18 during 16-18 hours. That evaluation was assessed by performing the glucose uptake assay 
using the fluorescent glucose analogue 2-NBDG, which gives an estimate of the glycolytic activity of the 
cells. Results show that CIML NK cells highly increased their metabolic activity, showing a value of 8.38 for 
the median fluorescence intensity (MFI) of 2-NBDG, while the median value for NK cells was 5.31 (Figure 
2A, left). Even if the proportion in blood is much higher for CD56dim cells, CD56bright cells were the ones 
who showed a higher glucose uptake rate in both NK and CIML NK cells, although not statistically 
significant (Figure 2A, right). 
 
On the other hand, we also analyzed whether those metabolic differences remained in time or not. In 
different clinical trials, IL-2 and IL-15 are used to promote proliferation and survival of NK cells (from 
https://clinicaltrials.gov/ct2/results?cond=&term=CIML&cntry=&state=&city=&dist=)so we 
decided to test in vitro the effect of these interleukins on NK cell metabolism. To assess that, non-




Results show similar glucose uptake values for both CIML15 and CIML2 NK cells (Figure 2B). 
Identification of CD56dim and CD56bright NK cell subsets was possible at day 0 but not at day 7 (Figure 2C). 
In short, we have determined that NK cells cultured for 16-18 hours with IL-12, IL-15 an IL-18 induced 
them to acquire an enhanced metabolic activity. Furthermore, this increased metabolism was a permanent 
condition for the next 7 days in which the cells were cultured with either IL-2 or IL-15 at low doses. 
 
Figure 2. Glucose uptake of non-preactivated natural killer (NK) and cytokine-induced memory-like (CIML) NK cells. 
(A) Bar graph showing glucose uptake, measured as the median fluorescence intensity (MFI) of 2-NBDG, of total 
control non pre-activated and CIML NK cells at day 0 (left) or CD56bright and CD56dim cells subsets (rigth). (B) Bar 
graph showing glucose uptake, measured as the MFI of 2-NBDG, of control non-preactivated (NK15) and CIML 
(CIML15 and CIML2) NK cells at day 7. (C) Representative pseudocolor plots showing NK cells at Day 0 (left) and at 
Day 7 (right). Each dot represents an independent experiment. *p < 0.05 and **p < 0.01. 
 
2-DG inhibits NK cells polyfunctionality 
Taking into account that glycolysis supports different important cellular processes and that CIML NK cells 
exhibit a greater glycolytic activity, the following aim was to evaluate the importance of that metabolic 
pathway for NK cells effector functions. To assess that, we co-cultured both control non-preactivated NK 
cells and CIML NK cells with K562 target cells in the presence and absence of 2-deoxy-D-glucose (2DG), a 




MIP-1β, and the expression of the degranulation marker CD107a, in control non-preactivated and CIML NK 
cells. IFNγ is considered the model NK cell cytokine and its production is known to activate antigen-
presenting cells (APCs) (Capuano et al., 2019). TNF is a major proinflammatory cytokine that is key fighting 
against virus and tumors, since it activates macrophage killing (Wang, Jaw, Stutzman, Zou, & Sun, 2012). 
Moreover, MIP-1β develops chemotactic and proinflammatory effects contributing to the recruitment of 
dendritic cells in the tumor microenvironment (Maurer & von Stebut, 2004; Vilgelm & Richmond, 2019). 
Last, CD107a is a highly glycosylated lysosomal-associated membrane protein (LAMP-1) that has been 
described as a marker of NK cell degranulation (Aktas et al., 2009; Alter et al., 2004; Cohnen et al., 2013). 
Therefore, these four molecules are good markers to determine NK cells functionality.  
First, we observed how due to IL-12/15/18 pre-stimulation, CIML NK cells show a higher production of 
IFNγ, TNFα and MIP1β, and expression of CD107a compared to control NK cells (Figure 3A). When 
stimulated with K562 target cells, both control NK and CIML NK cells exhibit increased functions (Figure 
3B), compared to those NK and CIML NK cells co-cultured with both K562 and 2-DG.. These result 
regarding upregulation of the effector functions are in accordance with what has been already reported 
(Cooper et al., 2009; Romee et al., 2016) about CIML NK cells restimulation and their enhanced 
functionality.  Last, we evaluated the polyfunctionality, which is defined as the capacity of cells to produce 
multiple cytokines and/or degranulate at the same time, of non-preactivated NK and CIML NK cells, in the 
presence and absence of 2-DG, which is a glycolytic inhibitor that inhibits the glycolytic enzyme hexokinase 
II (Pajak et al., 2019). We determined the polyfunctionality index using Funky Cell software (Larsen et al., 
2012). As expected, incubation with 2-DG not only diminishes the effect in the individual cytokine 
production and degranulation, but also reduces NK cells polyfunctionality (Table 1 and Figure 3), since it 
inhibits the glycolytic pathway and, therefore, ATP production. Focusing on CIML NK cells co-cultured 
with K562 target cells, we observed that triple positive cells (i.e. cells that are positive for three of the four 
measured functions) are the majority of the cells, followed by the quadruple and double positive cells. When 
incubated with the glycolytic inhibitor, we see how those percentages diminshe, and the majority of the cells 
become those that exhibit one effector function (Table 1).  
Table 1. Polyfunctionality indexes of control and CIML NK cells. First column shows the 
calculated polyfunctionality index for each cell subset. Adjacent columns show the percentage of 
cells with 4 (++++), 3 (+++-), 2 (++--), 1(+---) or 0 (----) functions, defining a function as the 




Figure 3. Effect of glycolysis inhibition on the effector functions of control non-preactivated and CIML NK cells. Bar 
graphs show the percentage of control and CIML NK cells that produce IFNγ, TNF or MIP-1β, or degranulate 
(measured as CD107a expression), in the presence and absence of 2-DG. Results were obtained (A) after 16-18 hours 
incubation and (B) after 16-18 hours incubation plus additional 7 hours co-cultivation with K562 target cells. *p < 0.05 
and **p < 0.01. 
 
DISCUSSION 
NK cells, and especially CIML NK cells, have become a promising tool in cancer immunotherapy (Capuano 




et al., 2017), in particular against acute myeloid leukemia (AML) (Mao et al., 2016; Uppendahl et al., 2019), 
where complete remissions have been observed after adoptive cell therapies with CIML NK cells (Romee et 
al., 2016). NK cells can get activated by different ways, being one via interleukin-mediated signals as it has 
been described with a mixture of IL-12, IL-15 and IL-18 (Cooper et al., 2009), where NK cells acquired a 
memory-like state in the absence of antigen stimulation. After activation, NK cells secrete cytokines and 
cytolytic granules containing perforin/granzyme B and others. These effector functions depend on the 
metabolic status of the cells (Assmann et al., 2017; Chang et al., 2013; Terrén et al., 2019). 
 
Following NK cell activation with interleukins, it has been demonstrated an increase of both OXPHOS and 
glycolysis, increasing the expression of glycolytic enzymes and other important nutrient transporters 
(Gardiner, 2019). In our study, we have observed how NK cells incubated with IL-12, IL-15 and IL-18 
acquire a preactivated state (CIML NK cells) and have higher glucose uptake rate, and indirect measure of 
glycolytic rate (Figure 2A). After incubation of CIML NK cells with low doses IL-15 and IL-2 separately for 
seven days, we have seen how the high glycolytic rates are maintained (Figure 2B), indicating that the 
glycolytic pathway is relevant for these cells and that metabolic reprogramming induced by IL-12, IL-15 and 
IL-18 stimulation is not transient. Previous studies suggest that CD56bright cells have a greater cytokine 
secretion capacity than CD56dim NK cells (Wagner et al., 2017). Regarding our assays, we see that the 
CD56bright subset exhibits a major glycolytic rate, also in agreement whit what Keating et al. reported in 
2016. Therefore, even if this cell population appears in a very low percentage in peripheral blood, this 
enhanced cytokine production might be strongly related to that upgraded metabolism and the fact that 
CD56bright NK cells express high levels of interleukin receptors. Then, in order to define if the glycolytic 
pathway actually is the primary metabolic pathway that follow CIML NK cells, we studied whether 
incubation with a glycolytic inhibitor such as 2-DG could affect or not CIML NK cells effector functions. To 
assess that, we incubated non-preactivated NK and CIML NK cells with 2-DG and stimulated them with 
K562 targets cells, a myelogenous leukemia cell line (Klein et al., 1976), and last we measured the 
expression of three critical cytokines (IFNγ, MIP1β and TNF) and the degranulation marker CD107a. 
 
In our experiments we could assessed that CIML NK cells showed major polyfunctional capacity after 
restimulation with K562 target cells, leading to the appearance of different triple positive functional states 
(especially CD107a+ MIP1β+ IFNγ+ TNFα-) or even quadruple positive functional state (Table 1). Compared 
to control non-preactivated NK cells, differences in the increase of effector functions are very significant in 
CIML NK cells after restimulation with target cells like K562. When incubated with the glycolytic inhibitor 
2-DG, polyfunctionality diminished. Nevertheless, the production of IFNγ and expression of CD107a 
remained somehow high in CIML NK cells, probably due to their pre-activated status (Figure 3). Expression 
of CD107a confirms that CIML NK cells continue degranulating despite inhibiting glycolysis. Moreover, 
regarding IFN-gamma expression, it has been suggested that the enzyme Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) appears to bind IFNγ mRNA, thus repressing its translation, as it has been 




triggered, this GAPDH acts as a glycolytic enzyme and does not impair the translation of IFNγ mRNA 
(Gardiner, 2019). This correlates with the importance that has been described for the glycolytic pathway 
regarding NK cells, since inhibition of that path may cause GAPDH to strongly bind mRNA from IFNγ, 
inhibiting cells from its production. Therefore, it is again reflected that pre-activation of NK cells with 
interleukins, among other signals and pathways, is a key tool (Terrén et al., 2018; Uppendahl et al., 2019) 
since cytokines can affect metabolism, in this case leading to the release of the IFNγ mRNA from GAPDH 
and enhancing its production and function. 
 
However, not only glycolysis and OXPHOS are key pathways involved in CIML NK cells effector 
functions. It has been reported that after interaction of non-preactivated NK and CIML NK cells with IL-15, 
three primary pathways get activated: JAK1-3/STAT3-5, PI3K/Akt/mTOR and Ras/Raf/MEK/ERK 
(Donnelly et al., 2014; Mao et al., 2016; Marçais et al., 2014). When PI3K and MEK are inhibited, it is 
observed a decrease on the cytotoxic proteins expression in CD56bright NK cells following IL-15 priming and 
killing of K562 leukemia target cells is significantly reduced. These two pathways had a lower effect on 
CD56dim NK cells, but killing was significantly reduced also (Donnelly et al., 2014; Keating et al., 2016; 
Wagner et al., 2017). Last, the sterol regulatory element-binding protein (SREBP) which controls the citrate-
malate shuttle, also appears to be increased in NK cells incubated with IL-2 and IL-12 meaning it is key for 
controlling NK cells metabolic configuration (O’Brien & Finlay, 2019; Terrén et al., 2019). Moreover, it has 
been demonstrated that after inhibition of SREBP, CIML NK cells lose their anti-tumor activity (Assmann et 
al., 2017). However, the role of SREBPs in the metabolic reprogramming of human CIML NK cells is still 
poorly understood, so it might be an interesting field to study. 
 
CONCLUSIONS  
First, this work shows how metabolism, specifically the glycolytic pathway, is a fundamental process for the 
effector functions by both non-preactivated NK and CIML NK cells. Moreover, we confirmed that the pre-
activated state of CIML NK cells leads to higher glycolytic rates, suggesting that these cells are 
metabolically more active and, therefore, exhibit improved functions. Last, we confirmed that CIML NK 
cells itself exhibit potent effector functions that are even increased when restimulated with K562 target cells, 
leading to a very high polyfunctional index. Regarding metabolism, we observed that inhibition of the 
glycolytic pathway diminished polyfunctionality, although production of IFNγ and expression of CD107a is 
less affected than TNFα and MIP1β production. All these results suggest that the generation of CIML NK 
cells is a promising tool for future oncological immunotherapies, and that studies related to their metabolic 
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